JP2020535423A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535423A5
JP2020535423A5 JP2020517797A JP2020517797A JP2020535423A5 JP 2020535423 A5 JP2020535423 A5 JP 2020535423A5 JP 2020517797 A JP2020517797 A JP 2020517797A JP 2020517797 A JP2020517797 A JP 2020517797A JP 2020535423 A5 JP2020535423 A5 JP 2020535423A5
Authority
JP
Japan
Prior art keywords
fgf
2sdng
compound
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517797A
Other languages
English (en)
Japanese (ja)
Other versions
JP7418324B2 (ja
JP2020535423A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/076391 external-priority patent/WO2019063756A1/en
Publication of JP2020535423A publication Critical patent/JP2020535423A/ja
Publication of JP2020535423A5 publication Critical patent/JP2020535423A5/ja
Application granted granted Critical
Publication of JP7418324B2 publication Critical patent/JP7418324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517797A 2017-09-29 2018-09-28 Fgf-18化合物に対する反応性を予測する炎症バイオマーカー Active JP7418324B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194169.3 2017-09-29
EP17194169 2017-09-29
EP18169317.7 2018-04-25
EP18169317 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND

Publications (3)

Publication Number Publication Date
JP2020535423A JP2020535423A (ja) 2020-12-03
JP2020535423A5 true JP2020535423A5 (cg-RX-API-DMAC7.html) 2021-11-04
JP7418324B2 JP7418324B2 (ja) 2024-01-19

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517797A Active JP7418324B2 (ja) 2017-09-29 2018-09-28 Fgf-18化合物に対する反応性を予測する炎症バイオマーカー

Country Status (16)

Country Link
US (2) US11467169B2 (cg-RX-API-DMAC7.html)
EP (1) EP3688468B1 (cg-RX-API-DMAC7.html)
JP (1) JP7418324B2 (cg-RX-API-DMAC7.html)
CN (1) CN111164429B (cg-RX-API-DMAC7.html)
AU (1) AU2018343980B2 (cg-RX-API-DMAC7.html)
CA (1) CA3075713A1 (cg-RX-API-DMAC7.html)
DK (1) DK3688468T3 (cg-RX-API-DMAC7.html)
ES (1) ES2918249T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220737T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058848T2 (cg-RX-API-DMAC7.html)
IL (1) IL273574B2 (cg-RX-API-DMAC7.html)
LT (1) LT3688468T (cg-RX-API-DMAC7.html)
PL (1) PL3688468T3 (cg-RX-API-DMAC7.html)
RS (1) RS63292B1 (cg-RX-API-DMAC7.html)
SI (1) SI3688468T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019063756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
TW201536320A (zh) * 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Similar Documents

Publication Publication Date Title
Muruganandam et al. Biomarkers in the pathogenesis, diagnosis, and treatment of systemic sclerosis
ES2660112T3 (es) Composiciones para el tratamiento de artritis reumatoide y métodos de uso de las mismas
JP2019529350A5 (cg-RX-API-DMAC7.html)
RU2015146419A (ru) Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
JP2023538906A5 (cg-RX-API-DMAC7.html)
JP2016524592A5 (cg-RX-API-DMAC7.html)
JP2015530868A5 (cg-RX-API-DMAC7.html)
JP2018508462A5 (cg-RX-API-DMAC7.html)
Tandon et al. Unraveling links between chronic inflammation and long COVID: workshop report
JP2020535436A5 (cg-RX-API-DMAC7.html)
JP2013514073A5 (cg-RX-API-DMAC7.html)
JP2013500941A5 (cg-RX-API-DMAC7.html)
JP2010501163A5 (cg-RX-API-DMAC7.html)
JP2015508063A5 (cg-RX-API-DMAC7.html)
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
JP2014527398A5 (cg-RX-API-DMAC7.html)
JP2017522555A5 (cg-RX-API-DMAC7.html)
WO2017184895A3 (en) Compositions and methods related to κ180 dimethylated h1.0 protein
RU2015144699A (ru) Адреномедуллин для направленной терапии по снижению кровяного давления
JP2019528285A5 (cg-RX-API-DMAC7.html)
JP2017519006A5 (cg-RX-API-DMAC7.html)
HRP20191145T1 (hr) Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak
JP2015505245A5 (cg-RX-API-DMAC7.html)
JP2009545526A5 (cg-RX-API-DMAC7.html)
RU2019102943A (ru) Составы на основе антитела